Micreos Human Health Enrolles World's First Endolysin-drug as a Therapy for Atopic Dermatitis

Micreos | September 22, 2020

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardless of antibiotic resistance, while preserving the skin microbiome. XZ.700 specifically targets Staphylococcus aureus (S. aureus), a bacterium that is considered to be a causative and aggravating trigger for atopic dermatitis, and viewed as an independent cause of itch, irritation and infection. "The targeted removal of one particular bacterial species, S. aureus, from the skin microbiome, while preserving the beneficial ones is a fundamental new way to treat atopic dermatitis," says dermatologist Dr. Peter Lio, Scientific Advisor for Micreos and Scientific Advisory Board member for the National Eczema Association. XZ.700 is one of several endolysins Micreos has in its portfolio. A structurally similar endolysin, SA.100, is used in the company's over the counter (OTC) products for inflammatory skin disorders (e.g. acne and rosacea), found in the Gladskin range, which have been on the market since 2013. Data obtained in earlier Gladskin studies and feedback from doctors and thousands of customers support the pharmaceutical development program: "I am very encouraged by my experience with Gladskin and I am awaiting the findings with great anticipation." In this study, conducted in The Netherlands, XZ.700 will be tested for its safety as well as pharmacodynamics and efficacy in 48 patients with atopic dermatitis. They will be treated for 14 days with a cream containing XZ.700 at three different concentrations or placebo. Micreos expects to finish the study and report the results towards the end of 2021.


Recombinant DNA Process Animation for school assignment.

Other News

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

SOPHiA GENETICS | March 08, 2022

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway and is linked with the development of certain cancers. It is also an important predictor of tumor response to treatment with PARP inhibitors. Molecular testing of tumor samples using SOPHiA DDM enables simultaneous detection of both HRR mutations that can cause HRD, including those in the BRCA1 and BRCA2 genes, and the accumulated damage to genomic integrity that can result from them, using shallow whole-genome Next Generation Sequencing. SOPHiA GENETICS is collaborating with AstraZeneca, aiming to expand access to in-house HRD testing across European laboratories and institutions. Providing laboratories with innovative solutions to enable locally-delivered HRD testing is critically important, particularly in settings such as advanced ovarian cancer, where approximately half of all newly diagnosed patients have HRD-positive tumors, We are pleased to work with SOPHiA GENETICS in their mission to empower their laboratory customers and increase the range of options available for HRD detection." Kristina Rodnikova, SVP Global Oncology Diagnostics at AstraZeneca. To combat current challenges with HRD detection offerings, the SOPHiA DDM HRD Solution provides laboratories and institutions with a decentralized approach to HRD testing for tumor samples. The SOPHiA DDM HRD Solution allows the user to retain full ownership of their data and save time and expenses, while also offering comprehensive genomic insights powered by deep learning algorithms. We at SOPHiA GENETICS have always been on a mission to improve health outcomes by advancing data-driven medicine, which is why I am extremely excited to announce the launch of our new HRD research solution, Our SOPHiA DDM HRD Solution will provide researchers and other healthcare professionals with a decentralized approach to fully integrated HRD testing, enabling the HRD status of more advanced ovarian cancer cases to be determined without reliance on send-out testing solutions." Dr. Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally.

Read More


Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

Taysha Gene Therapies | December 16, 2021

Taysha Gene Therapies Inc. a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that it has been added to the Nasdaq Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. “We are pleased to announce Taysha’s inclusion in the Nasdaq Biotechnology Index. As we continue to advance our broad pipeline and execute on our near-term clinical and regulatory milestones, inclusion in this index will enhance our visibility and expand awareness of our story with investors.” RA Session II, President, Founder and CEO of Taysha The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December. About Taysha Gene Therapies Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.

Read More


FEN Industries Earns USDA Certified Biobased Product Label for Terreplenish® Soil Microbes

FEN Industries | February 22, 2022

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have played an increasingly important role in reducing greenhouse gas (GHG) emissions that exacerbate global climate change. Biobased products are cost-comparative, readily available, and perform as well as or better than their conventional counterparts. "Terreplenish® Soil Regenerating Microbes sequester 45-60lbs of nitrogen per growing season, providing an alternative to petroleum derived fertilizer products," Cathy Scratch, FEN Founder "We applaud FEN Industries for earning the USDA Certified Biobased Product label," said Kate Lewis, USDA BioPreferred Program. "Products like Terreplenish® contribute to an ever-expanding marketplace that adds value to renewable agriculture commodities and decreases our reliance on petroleum." According to a report that USDA released in 2019, biobased products contributed more than $500 billion to the U.S. economy and estimated reduction of fossil fuels associated GHG emissions from biobased products equivalent to approximately 12 million metric tons of carbon dioxide (CO2). The increased production of biobased products contributes to the development and expansion of the U.S. bioeconomy - where society looks to agriculture for sustainable sources of fuel, energy, chemicals, and products. About FEN Industries: A fen is a unique ecosystem that nurtures bio-nutrient diversity and conserves water as a necessary buffer between habitats that naturally siphons toxins. FEN Industries is an accelerated composting technology company that creates Terreplenish® - an OMRI Listed, 97% certified biobased product and approved by California Department of Agriculture. The high cost of nitrogen fertilizer can be reduced significantly with the addition of Terreplenish® soil regenerating microbes while providing many other benefits like pathogen control, phosphorous control, and better plant emergence scores. Additional revenue can be generated by participating in the many phosphorous reduction programs and carbon sequestration projects.

Read More


Evonetix Granted Patent for Technology Enabling Thermally-Controlled DNA Synthesis

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used. Evonetix’s novel approach to parallel DNA synthesis is underpinned by precise, independent, control of temperature at thousands of individual synthesis sites across the surface of a silicon chip. In contrast to conventional approaches, which use acid deprotection to control the synthesis cycle, Evonetix uses thermal control with semiconductor-based arrays. This offers greater accuracy and selectivity to deprotect sequences at the correct point to add the next nucleotide and remove mismatching sequences. Thermal control of DNA synthesis enables highly parallel synthesis and gives the ability to work through sequences that are hard to synthesise using conventional techniques and to remove errors during the assembly of gene sequences through temperature mediated error removal. There is currently an unmet need in the synthetic biology industry for long, accurate, DNA sequences, and the ability to remove errors during assembly allows researchers to achieve longer strands of DNA, and run applications such as gene synthesis, CRISPR screening, and protein engineering. Securing this patent to cover our core technology adds further strength to our IP portfolio and underlines Evonetix’s position as leaders in our field. Our technology will give researchers the capabilities of service centres in their own lab, accelerating the advancement of synthetic biology and opening new possibilities in this exciting market.” Matthew Hayes, Chief Technology Officer at Evonetix.

Read More